EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure

Rannissa Puspita Jayanti iD, Yong-Soon Cho iD, Soedarsono Soedarsono iD, Hyo-Jung Kim, Jiyeon Kang, Jehun Kim, Jee Youn Oh, Bo Hyoung Kang, Jick Hwan Ha, Jin-Woo Kim, Ni Made Mertaniasih, Tutik Kusmiati iD und 8 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0340133 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS One, 2026. Verfasst von Rannissa Puspita Jayanti und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Pyrazinamide, Antitubercular Agents, Tuberculosis, Diabetes Mellitus. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT of Republic of Korea, Ministry of Research and Technology/National Agency for Research and Innovation of Indonesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus (DM), a common comorbidity in tuberculosis (TB) patients, can alter the pharmacokinetics (PK) of TB drugs. Additionally, clinical and demographic differences may contribute to interethnic PK variability. However, current WHO-recommended doses for pyrazinamide (PZA) do not account for those factors. We aimed to evaluate factors related to interindividual variability (IIV) and interethnic differences in the PK of PZA between Korean and Indonesian patients with TB. Demographics, clinical characteristics, and PZA concentrations obtained from hospitals in both countries were used for model establishment. Population PK models were developed using the nonlinear mixed-effect method. A Monte Carlo simulation was performed sequentially to evaluate optimal PZA dosing strategies. A one-compartment model with allometric scaling adequately described the PK of PZA. Internal validation of the model showed good performance. No significant interethnic differences in PK parameters were observed. There were 23% and 26% increases in apparent clearance (CL/F) of Indonesian patients with DM (CL/F 3.18 L/h) and Korean patients aged > 60 years with DM (CL/F 3.5). PZA doses of 1000–1250 mg for patients of bodyweight < 40 kg and 1250 mg for older patients with DM in this weight band had a 90% probability of attaining the target AUC 0–24 ≥ 363 mg·h/L These findings indicate that DM strongly influenced IIV, particularly in older patients. We recommend higher PZA doses for patients

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinamideAntitubercular AgentsTuberculosisDiabetes MellitusHumansFemaleMiddle AgedMaleModels, BiologicalIndonesiaAdultCohort StudiesAgedMonte Carlo MethodRepublic of Korea

Substanzen

PyrazinamideAntitubercular Agents

Autor:innen und Institutionen

  • Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Republic of Korea.
  • Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.
  • Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Republic of Korea.
  • Sub-Pumonology Department of Internal Medicine, Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia.
  • Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.

ORCID-Profile: Rannissa Puspita Jayanti, Yong-Soon Cho, Soedarsono Soedarsono, Tutik Kusmiati, Hyeon-Jeong Seong

Förderung

  • Ministry of Science and ICT of Republic of Korea
  • Ministry of Research and Technology/National Agency for Research and Innovation of Indonesia

Zitieren

APA

Jayanti, R. P., Cho, Y. S., Soedarsono, S., Kim, H. J., Kang, J., Kim, J., Oh, J. Y., Kang, B. H., Ha, J. H., Kim, J. W., Mertaniasih, N. M., Kusmiati, T., Permatasari, A., Yuliwulandari, R., Kim, R., Seong, H. J., Ghim, J. L., Kim, D. H., Shin, J. G., & cPMTb (2026). Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure. PLOS One. https://doi.org/10.1371/journal.pone.0340133

Vancouver

Jayanti RP, Cho YS, Soedarsono S, Kim HJ, Kang J, Kim J, et al. Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure. PLOS One. 2026. doi:10.1371/journal.pone.0340133

BibTeX
@article{Jayanti2026,
  author = {Jayanti, Rannissa Puspita and Cho, Yong-Soon and Soedarsono, Soedarsono and Kim, Hyo-Jung and Kang, Jiyeon and Kim, Jehun and Oh, Jee Youn and Kang, Bo Hyoung and Ha, Jick Hwan and Kim, Jin-Woo and Mertaniasih, Ni Made and Kusmiati, Tutik and Permatasari, Ariani and Yuliwulandari, Rika and Kim, Ryunha and Seong, Hyeon-Jeong and Ghim, Jong-Lyul and Kim, Dong-Hyun and Shin, Jae-Gook and cPMTb, cPMTb},
  title = {Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0340133}
}
Kostenlos starten →